Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCA9QP)

Drug Name
Papaverine Drug Info
Synonyms
papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; Pavatym; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Cerespan; Papaverine [BAN]; Pavacot; Papaverina [Italian]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverine Hcl; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); Pamelon; Chlorhydrate de papaverine; Qua bid; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; Alapav; Cardiospan; Cardoverina; Ceraspan; Cerebid; Delapav; Dilaves; Dispamil; Drapavel; Durapav; Dynovas; Forpavin; Genabid; Mesotina; Myobid; Pameion; Panergon; Papacon; Papalease; Papaversan; Pavacap; Pavacels; Pavacen; Pavagen; Pavarine; Pavatest; Pavatine; Paverolan; Paveron; Pavnell; Vasal; PAP H; Papavarine chlorhydrate; Papaverine chlorohydrate; Papaverine monohydrochloride; Papaverinium chloride; Pavabid Hp; RS 47; TNP00305; Alapav (TN); Albatran (TN); Artegodan (TN); Cardiospan (TN); Cardioverina (TN); Cepaverin (TN); Cerebid (TN); Cerespan (TN); Delapav (TN); Dicertan (TN); Dilaves (TN); Dispamil (TN); Drapavel (TN); Durapav (TN); Dynovas (TN); Forpaven (TN); Houde (TN); Mesotina (TN); Myobid (TN); Opdensit (TN); Optenyl (TN); Pameion (TN); Pamelon (TN); Panergon (TN); Papacon (TN); Papalease (TN); Papanerin-hcl; Papaversan (TN); Pavabid (TN); Pavacap (TN); Pavacen (TN); Pavadel (TN); Pavadyl (TN); Pavagen (TN); Pavakey (TN); Pavased (TN); Pavatest (TN); Paverina (TN); Paverolan (TN); Paveron (TN); Pavnell (TN); Qua bid (TN); Ro-Papav; Therapav (TN); Vasal (TN); Vaso-Pav; Vasospan (TN); Papanerin-hcl (TN); Papaverin-Hamelin (TN); Papital TR; Paptial TR; Ro-Papav (TN); Spasmo-Nit (TN); Vaso-Pav (TN); Pap-Kaps-150 (TN); Papital TR (TN); Paptial TR (TN); Isoquinoline,6,7-dimethoxy-1-veratryl-(8CI); Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE
Therapeutic ClassVasodilator Agents
Cross-matching ID
PubChem CID
4680
ChEBI ID
CHEMBL19224
CAS Number
CAS 58-74-2
TTD Drug ID
D0NJ3V
VARIDT Drug ID
DR00967
INTEDE Drug ID
DR2299

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
ECM-receptor interaction 1.89 2.67e-2 80/88 (90.91%) COL6A2;THBS2;COL6A1;...
Focal adhesion 1.83 3.12e-2 180/201 (89.55%) IGF1;VEGFA;COL6A2;...
Protein digestion and absorption 1.82 2.38e-2 78/103 (75.73%) COL3A1;COL15A1;COL6A2;...
Valine, leucine and isoleucine degradation 1.74 4.45e-2 42/48 (87.5%) PCCB;AUH;DLD;...
NOD-like receptor signaling pathway -1.67 4.46e-2 145/181 (80.11%) CARD8;HSP90AB1;MYD88;...
Neutrophil extracellular trap formation -1.69 3.98e-2 101/189 (53.44%) PIK3R1;SYK;PLCB2;...
Tuberculosis -1.70 3.77e-2 159/180 (88.33%) CEBPG;CYP27B1;MYD88;...
Tyrosine metabolism -1.71 3.62e-2 30/36 (83.33%) ADH6;HPD;ADH1A;...
Pertussis -1.74 2.84e-2 64/76 (84.21%) RELA;IRF8;SFTPA2;...
Phagosome -1.74 3.12e-2 118/152 (77.63%) COLEC11;DYNC1LI2;HLA-DMB;...
Mitophagy -1.75 3.10e-2 56/68 (82.35%) UBC;HRAS;GABARAPL1;...
Lysosome -1.75 3.48e-2 115/128 (89.84%) PSAP;LGMN;ATP6V0B;...
Steroid biosynthesis -1.75 3.98e-2 19/20 (95%) FDFT1;CYP51A1;LSS;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.75 4.64e-2 79/89 (88.76%) PIK3R3;IKBKG;HRAS;...
Mineral absorption -1.79 3.12e-2 48/60 (80%) MT2A;MT1M;SLC26A3;...
T cell receptor signaling pathway -1.82 2.79e-2 93/104 (89.42%) CSF2;NCK1;CD28;...
Lipid and atherosclerosis -1.90 1.49e-2 190/215 (88.37%) PIK3R3;BID;IKBKG;...
Osteoclast differentiation -1.91 2.23e-2 117/127 (92.13%) TRAF6;BLNK;SOCS1;...
Legionellosis -1.99 1.11e-2 51/57 (89.47%) RELA;CR1;RAB1A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H, 48H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H